Jenny Duan picked up her Stanford diploma on a weekend in June 2026. Days earlier, the 21-year-old had closed an $11.6 million seed round for her company, Clair Health, led by Khosla Ventures. That timing wasn’t a coincidence so much as a pattern: Duan had spent the better part of her college years building the company alongside her degree, not after it.
Duan is the co-founder and CEO of Clair Health, a San Francisco startup building what it calls the first noninvasive, continuous hormone-monitoring wearable for women. Jenny Duan Clair Health is a founder story about a personal frustration, an underfunded corner of medicine, and a bet that the same sensors already sitting on millions of wrists have been missing half the picture all along.
Where Jenny Duan Came From
Duan’s path to Clair Health started well before Stanford. In high school, she worked with women experiencing domestic violence and homelessness through Rose Haven, a nonprofit in Oregon, according to Women of Wearables. There, she watched healthcare providers repeatedly dismiss women’s symptoms for lack of quantitative data, an experience she has said stayed with her long after.
At Stanford, Duan studied symbolic systems with a focus on AI ethics and the social internet, graduating early. It was there she met Abhinav Agarwal, who brought a background in health tech and wearables and now serves as Clair Health’s chief technology officer, according to Duan’s LinkedIn profile. Duan has also cited a specific statistic that crystallized her thinking: women were not required to be included in U.S. clinical trials until 1993, a fact she says she “came across” as an undergraduate and could not stop thinking about, according to Her Campus.
Why Women’s Health Needed Clair Health
The immediate spark was personal. Duan has an irregular menstrual cycle, and she spent months logging symptoms into conventional period-tracking apps hoping the data would eventually surface something useful. It never did. “I was logging data month over month, but nothing changed,” she told Her Campus, describing the gap between what her body was doing and what the app understood about it.
That personal frustration sits inside a much larger, well-documented gap in medical research. Because women were largely excluded from U.S. clinical trials until the 1990s, women’s health, and hormonal health in particular, remains comparatively underfunded and understudied relative to men’s health. Duan has put it more bluntly in her own words: “Women have been treated like an afterthought for far too long.”
How Clair Health Actually Works
Clair Health’s wrist-worn wearable does not measure hormones directly through blood, saliva, or urine, the way conventional hormone testing does. Instead, the company uses machine learning models to infer hormonal activity from physiological signals wearables already collect, including skin temperature, heart rate, sleep patterns, and breathing metrics, according to HLTH. The device integrates 10 biosensors and more than 130 proprietary biomarkers and physiological signals to estimate levels of estrogen, progesterone, luteinizing hormone, and follicle-stimulating hormone in real time, without needles or lab draws.
The company has also built its architecture around privacy from the outset: hormone inference and analysis happen on-device rather than in the cloud, meaning sensitive health data does not leave a user’s phone, according to Clair Health’s own account of its design choices. That distinction matters in a wearable industry that has faced real consumer skepticism around health data privacy in recent years. The device itself, with a rose-gold housing and soft band, is designed to read more like jewelry than a fitness tracker, part of the company’s broader pitch that hormone monitoring deserves its own design language rather than borrowing from generic step-counters.
The Money Behind Clair Health: $11.6 Million
Jenny Duan Clair Health raised $11.6 million in seed funding, announced in June 2026 and led by Khosla Ventures, with participation from a16z Speedrun, Brydge Club, Treehub (AI Health Fund), Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki, the co-founder of 23andMe. Treehub, according to its own team’s public comments, was the company’s earliest institutional backer, investing before the round that made headlines.
Alex Morgan, MD, PhD, a partner at Khosla Ventures, pointed to recent advances in sensors, combined with cross-modal learning approaches in AI, as what makes Clair Health’s approach possible now in a way it wouldn’t have been a few years earlier. The funding will support the wearable’s launch and ongoing clinical research, a category Clair Health and its backers describe as chronically underfunded relative to its scale of impact.
What Clair Health Has Proven So Far
Clair Health has not yet shipped its wearable, with launch planned for November 2026, but the company says early testing has already identified nine distinct sub-phases within the female hormone cycle, challenging the long-standing four-phase model that has anchored women’s health research and period-tracking apps for decades. That finding, if it holds up under further scrutiny, would be a meaningful research contribution independent of whether the commercial product succeeds.
More than 25,000 people have joined Clair Health’s waitlist ahead of launch, a substantial pre-launch demand signal for a hardware product that does not yet exist on shelves. The company has publicly announced its intentions since February 2026, giving it several months of visibility before its funding round became widely reported. That waitlist figure is also notable in context: femtech products often struggle to build mainstream pre-launch attention outside dedicated women’s health communities, and a five-figure waitlist ahead of a hardware launch suggests Clair Health’s messaging has reached well beyond its most obvious audience.
Who’s Betting on Jenny Duan
The Jenny Duan Clair Health investor list mixes traditional venture capital with a notable roster of individual backers connected to women’s health and consumer technology. Anne Wojcicki’s participation as an angel investor carries particular symbolic weight: 23andMe, the company she co-founded, built one of the largest consumer genetic databases in the world, and her decision to back a hormone-data company signals a belief that female-specific biological data remains a meaningfully underbuilt category.
Khosla Ventures’ decision to lead the round, with a healthcare-focused partner overseeing the investment, gives Clair Health institutional credibility in a funding environment where femtech startups have historically struggled to attract the same capital as other health tech categories. The presence of both a major venture firm and individually recognizable health-industry names in the same round is itself a signal that investors increasingly see hormonal health data as a distinct, investable category rather than a niche subset of general wellness.
Clair Health Against the Competition
Clair Health is entering a wearables market where general fitness trackers like Oura and WHOOP have begun expanding into women’s health features, layering menstrual cycle tracking on top of platforms originally built around sleep and recovery metrics for a broader, gender-neutral audience. Clair Health’s bet is that hormone monitoring is different enough, and important enough, to justify a wearable built specifically around it from the ground up, rather than added as a feature to an existing device.
That positioning is both an opportunity and a real commercial risk. Building a standalone hardware company is a harder path than adding a software feature to an established wearable with millions of existing users, and Clair Health will need to prove its inference-based approach is accurate enough to earn trust in a category where medical credibility matters enormously. Unlike a software feature that can be updated overnight based on user feedback, hardware companies face longer iteration cycles, meaning Clair Health’s first-generation device will need to perform reliably close to launch rather than improving gradually the way a mobile app might.
Where Jenny Duan Takes It From Here
With its wearable still months from launch, Clair Health’s near-term priorities are straightforward: ship the device in November 2026, continue clinical research to validate its hormone-inference models, and convert its 25,000-person waitlist into paying customers. Longer term, Duan has described Clair Health’s ambition as building a foundational hormonal data layer for women, tracking hormonal health from a woman’s first period through perimenopause and beyond, rather than a single point-in-time health snapshot.
Whether that vision holds will depend heavily on how accurately Clair Health’s models perform once real-world data starts flowing in from actual users, rather than the controlled testing conditions the company has relied on so far.
What Other Founders Can Take From This
Duan’s path offers a few clear takeaways for other early-career founders. First, the idea for Clair Health did not come from market research; it came from her own unresolved frustration with existing period-tracking tools, then got sharpened by a specific, credible statistic she carried with her for years. Second, recruiting a technical co-founder with direct wearables and health tech experience, in Agarwal’s case, let Duan focus on the parts of the business, brand, fundraising, and go-to-market, where her own instincts were strongest. Third, building genuine pre-launch demand, in this case a 25,000-person waitlist months before shipping, gave Clair Health leverage with investors that pure technology promises alone would not have provided.
Frequently Asked Questions
What is Clair Health? Clair Health is a San Francisco startup building a noninvasive, continuous hormone-monitoring wearable for women, using AI to infer hormone levels from physiological signals rather than blood, saliva, or urine testing.
Who founded Clair Health? Clair Health was co-founded by Jenny Duan, who serves as CEO, and Abhinav Agarwal, who serves as chief technology officer. Both are Stanford University graduates who met on campus in 2025.
How much funding has Clair Health raised? Clair Health raised $11.6 million in seed funding, announced in June 2026 and led by Khosla Ventures, with participation from a16z Speedrun, Brydge Club, Treehub, and angel investor Anne Wojcicki, co-founder of 23andMe.
How does Clair Health’s wearable work? The device uses 10 biosensors and more than 130 biomarkers and physiological signals, including skin temperature, heart rate, and sleep data, to infer levels of estrogen, progesterone, LH, and FSH through machine learning rather than direct hormone testing.
When does Clair Health launch? Clair Health’s wrist-worn device and companion app are planned to launch in November 2026, with more than 25,000 people already on the company’s waitlist.
How is Clair Health different from Oura or WHOOP? Unlike general fitness wearables that have added women’s health features to existing platforms, Clair Health was built from the ground up specifically around continuous hormone monitoring, rather than as an added feature to a broader wellness tracker.
Conclusion
Whether Clair Health’s inference-based approach to hormone tracking holds up once thousands of real users start wearing the device will say a lot about how much of women’s health data science has simply been waiting for the right sensors and the right team to arrive. For now, Jenny Duan’s path, from a nonprofit in Oregon to a Stanford diploma to an $11.6 million seed round in the same week, has already made Clair Health one of the more closely watched femtech launches of 2026. Readers curious about other founders building at the intersection of hardware and AI inference may also want to look at Jay Li’s wearable sensor glove at Proception, Baran Ataş’s behavioral prediction engine at Talp, or Puru Rastogi’s physical AI work at Mowito.
